Identification of a basal-like subtype of breast ductal carcinoma in situ. Export

@article{citeulike:1289916, abstract = {Microarray profiling of invasive breast carcinomas has identified subtypes including luminal A, luminal B, HER2-overexpressing, and basal-like. The poor-prognosis, basal-like tumors have been immunohistochemically characterized as estrogen receptor (ER)-negative, HER2/neu-negative, and cytokeratin 5/6-positive and/or epidermal growth factor receptor (EGFR)-positive. The aim of this study was to determine the prevalence of basal-like ductal carcinoma in situ in a population-based series of cases using immunohistochemical surrogates. A total of 245 pure ductal carcinoma in situ cases from a population-based, case-control study were evaluated for histologic characteristics and immunostained for ER, HER2/neu, EGFR, cytokeratin 5/6, p53, and Ki-67. The subtypes were defined as: luminal A (ER+, HER2-), luminal B (ER+, HER2+), HER2 positive (ER-, HER2+), and basal-like (ER-, HER2-, EGFR+, and/or cytokeratin 5/6+). The prevalence of breast cancer subtypes was basal-like (n = 19 [8\%]); luminal A, n = 149 (61\%); luminal B, n = 23 (9\%); and HER2+/ER-, n = 38 (16\%). Sixteen tumors (6\%) were unclassified (negative for all 4 defining markers). The basal-like subtype was associated with unfavorable prognostic variables including high-grade nuclei (P < .0001), p53 overexpression (P < .0001), and elevated Ki-67 index (P < .0001). These studies demonstrate the presence of a basal-like in situ carcinoma, a potential precursor lesion to invasive basal-like carcinoma.}, address = {Department of Pathology and Lab Medicine, University of North Carolina, Chapel Hill, NC 27599-7525, USA. cal@med.unc.edu}, author = {Livasy, C. A. and Perou, C. M. and Karaca, G. and Cowan, D. W. and Maia, D. and Jackson, S. and Tse, C. K. and Nyante, S. and Millikan, R. C.}, citeulike-article-id = {1289916}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/j.humpath.2006.08.017}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/17234468}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=17234468}, citeulike-linkout-3 = {http://www.sciencedirect.com/science/article/B6WGD-4MV0K76-6/2/804d4831d066b40ea690a46ed6e15079}, doi = {10.1016/j.humpath.2006.08.017}, issn = {0046-8177}, journal = {Hum Pathol}, keywords = {basal-like, breast, cancer, dcis, subtypes}, month = {February}, number = {2}, pages = {197--204}, posted-at = {2008-09-14 22:03:22}, priority = {4}, title = {Identification of a basal-like subtype of breast ductal carcinoma in situ.}, url = {http://dx.doi.org/10.1016/j.humpath.2006.08.017}, volume = {38}, year = {2007} }

TY - JOUR ID - citeulike:1289916 L3 - citeulike-article-id:1289916 N2 - Microarray profiling of invasive breast carcinomas has identified subtypes including luminal A, luminal B, HER2-overexpressing, and basal-like. The poor-prognosis, basal-like tumors have been immunohistochemically characterized as estrogen receptor (ER)-negative, HER2/neu-negative, and cytokeratin 5/6-positive and/or epidermal growth factor receptor (EGFR)-positive. The aim of this study was to determine the prevalence of basal-like ductal carcinoma in situ in a population-based series of cases using immunohistochemical surrogates. A total of 245 pure ductal carcinoma in situ cases from a population-based, case-control study were evaluated for histologic characteristics and immunostained for ER, HER2/neu, EGFR, cytokeratin 5/6, p53, and Ki-67. The subtypes were defined as: luminal A (ER+, HER2-), luminal B (ER+, HER2+), HER2 positive (ER-, HER2+), and basal-like (ER-, HER2-, EGFR+, and/or cytokeratin 5/6+). The prevalence of breast cancer subtypes was basal-like (n = 19 [8%]); luminal A, n = 149 (61%); luminal B, n = 23 (9%); and HER2+/ER-, n = 38 (16%). Sixteen tumors (6%) were unclassified (negative for all 4 defining markers). The basal-like subtype was associated with unfavorable prognostic variables including high-grade nuclei (P < .0001), p53 overexpression (P < .0001), and elevated Ki-67 index (P < .0001). These studies demonstrate the presence of a basal-like in situ carcinoma, a potential precursor lesion to invasive basal-like carcinoma. IS - 2 JF - Hum Pathol SN - 0046-8177 AD - Department of Pathology and Lab Medicine, University of North Carolina, Chapel Hill, NC 27599-7525, USA. cal@med.unc.edu EP - 204 TI - Identification of a basal-like subtype of breast ductal carcinoma in situ. VL - 38 SP - 197 KW - basal-like KW - breast KW - cancer KW - dcis KW - subtypes AU - Livasy, CA AU - Perou, CM AU - Karaca, G AU - Cowan, DW AU - Maia, D AU - Jackson, S AU - Tse, CK AU - Nyante, S AU - Millikan, RC PY - 2007/02// UR - http://dx.doi.org/10.1016/j.humpath.2006.08.017 ER -